Skip to main content
SpringerLink
Log in

Stem cells—a hard sell to investors

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Market performance of 5 'stem cell' companies illustrates the volatility of the group compared with the Nasdaq general biotech stock index.

Author information

Authors and Affiliations

  1. SV Life Sciences,

    Lutz B Giebel

  2. Cythera Inc.,

    Lutz B Giebel

  3. Novocell Inc.,

    Lutz B Giebel

Authors
  1. Lutz B Giebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giebel, L. Stem cells—a hard sell to investors. Nat Biotechnol 23, 798–800 (2005). https://doi.org/10.1038/nbt0705-798

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0705-798

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation